OR WAIT null SECS
September 13, 2021
Boehringer Ingelheim and Twist Bioscience will use Twist’s antibody libraries to discover therapeutic antibody candidates.
September 10, 2021
Janssen’s Invega Hayfera is the first six-month injectable schizophrenia treatment approved by FDA.
Vector Laboratories has completed a $124 million cash buyout backed by Thompson Street Capital Partners and will begin an acquisition strategy to expand protein detection capabilities.
ABPI has announced that eight leaders from the patient and health charity sector have been chosen to join its new Patient Advisory Council.
ILC Therapeutics, has successfully closed a £3.5 million (US$4.9 million) pre-initial public offering (IPO) funding round.
NICE has reconsidered its decision on Janssen's Erleada (apalutamide), issuing two positive final appraisal determinations (FADs) on the therapy.
NICE has recommended tofacitinib (Xeljanz, Pfizer)as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis.
Sterling Pharma Solutions has invested in a center of excellence for research into commercial applications of continuous flow chemistry at its site in Dudley, UK.
Nanoform and Herantis Pharma's proof of concept project evaluating the application of the nanoforming process has been successful.
Avantor has acquired the Masterflex bioprocessing business and related assets of Antylia Scientific.